Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kezar Life Sciences (KZR) Other Accumulated Expenses (2021 - 2023)

Kezar Life Sciences' Other Accumulated Expenses history spans 3 years, with the latest figure at $106000.0 for Q4 2023.

  • For Q4 2023, Other Accumulated Expenses fell 60.0% year-over-year to $106000.0; the TTM value through Dec 2023 reached $106000.0, down 60.0%, while the annual FY2023 figure was $106000.0, 60.0% down from the prior year.
  • Other Accumulated Expenses for Q4 2023 was $106000.0 at Kezar Life Sciences, down from $265000.0 in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $265000.0 in Q4 2022 and bottomed at $99000.0 in Q4 2021.
  • The 3-year median for Other Accumulated Expenses is $141500.0 (2021), against an average of $161750.0.
  • The largest annual shift saw Other Accumulated Expenses soared 167.68% in 2022 before it crashed 60.0% in 2023.
  • A 3-year view of Other Accumulated Expenses shows it stood at $99000.0 in 2021, then skyrocketed by 167.68% to $265000.0 in 2022, then plummeted by 60.0% to $106000.0 in 2023.
  • Per Business Quant, the three most recent readings for KZR's Other Accumulated Expenses are $106000.0 (Q4 2023), $265000.0 (Q4 2022), and $99000.0 (Q4 2021).